SAN MATEO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 11th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 10, 2009. Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions immediately following the presentation.
Event: 11th Annual BIO CEO & Investor Conference Date: Tuesday, February 10, 2009 Time: 10:30 a.m. ET Place: Louis XVI, The Waldorf-Astoria
The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcast will be archived for 15 days.
About NeurogesX, Inc.
NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high concentration capsaicin patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. An NDA for Qutenza seeking approval for the management of pain due to PHN was submitted in Oct
|SOURCE NeurogesX, Inc.|
Copyright©2009 PR Newswire.
All rights reserved